在不利的环境下,Apolipoprotein E4和阿尔茨海默病的因果关系以及老化营养素的潜在干预
Gabriella C V Ciurleo1, Orleâncio G R de Azevedo1, Camila G M Carvalho1
1Laboratory of the Biology of Tissue Healing, Ontogeny and Nutrition, Department of Morphology and Institute of Biomedicine, School of Medicine, Federal University of Ceara, Fortaleza, Brazil.
Clinical nutrition ESPEN
|September 9, 2024
概括
APOE4基因变异可能会保护面临生命早期逆境的儿童,但会增加晚年阿尔茨海默病的风险. 公共卫生必须解决APOE4载体的这种双重风险,即早期和晚期的不良暴露.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 公共卫生 公共卫生
背景情况:
- 脂蛋白E (apoE) 在阿尔茨海默氏症 (AD) 病理生理学中发挥着关键作用.
- APOE4基因型是晚期发病的阿尔茨海默病的重要危险因素,同胞性现在被认为是家族遗传特征.
- 早期的生活逆境和暴露因素可以影响神经发育和长期健康结果.
研究的目的:
- 探索APOE4的潜在双重作用,在不同的生命阶段具有对抗作用.
- 突出APOE4在特定环境条件下的早期生命中的神经保护潜力.
- 提高人们对APOE4携带者因早期逆境和晚年暴露而面临的累积风险的认识.
主要方法:
- 这是一篇综合现有研究并提出新假设的意见论文.
- 关于APOE4功能,AD病原和环境影响的文献综述.
- 开发概念框架,将早期生命暴露组,APOE4与衰老联系起来.
主要成果:
- 在生命早期,APOE4可能会提供神经保护,特别是在暴露于肠道感染/营养不良时.
- 尽管APOE4在生命早期有好处,但随着年龄的增长,APOE4显著增加了患AD的风险.
- 患有APOE4的个体,不良早期生活条件和不健康的衰老生活方式有较高的认知衰退风险.
结论:
- APOE4表现出性,对抗性作用,在生命早期提供保护,但在以后带来风险.
- 需要公共卫生战略来识别和支持由于环境和遗传因素的结合而面临风险的APOE4载体.
- 抗衰老疗法可能对缓解这些脆弱个体的衰老相关疾病和认知障碍至关重要.
相关概念视频
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K


